Last reviewed · How we verify
NCT06337305
Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer
trial in Bladder Cancer in 74 participants. Completed in 19 August 2023.
19 August 2022
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 74 |
| Start date | 19 August 2020 |
| Primary completion | 19 August 2022 |
| Estimated completion | 19 August 2023 |
| Sites | 1 location across United States |
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
University of Kansas Medical Center
Who can join
18 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively.
Kennedy LN, Miller CS, May DN, Fruhauf E, et al · · 2025 · PMID 40296877 · DOI 10.1177/23523735251319180
Verify or expand the search:
- PubMed search for NCT06337305
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06337305 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06337305.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing